腎機能検査の世界市場-2023年～2030年

市場概要

世界の腎機能検査市場は、2022年に9億米ドルに達し、2030年には14億米ドルに達する好成長が予測されています。予測期間2023-2030年のCAGRは6.3%と予測されます。

腎機能検査は、腎臓や腎機能の障害を特定し、医師が適切な薬を処方するのを支援します。希釈検査、クリアランス検査、その他の種類の腎機能検査があります。体液過多による排尿障害、手足の浮腫、顔のむくみなどの腎臓疾患は、腎機能検査で特定できます。

市場の成長を促進する要因としては、FDAの承認や主要企業による腎機能検査の新製品の発売などが挙げられます。例えば、2022年7月12日、スマートフォンのカメラを医療機器に統合した世界のパイオニアであるHealthy.io社は、Minuteful Kidney検査が米国食品医薬品局（FDA）から家庭用として510（k）認可を取得したと発表しました。

市場力学

腎臓疾患の有病率の増加が腎機能検査市場の成長を牽引

慢性腎臓病の罹患率と有病率の世界の上昇は、世界の腎機能検査市場の成長を促進する主な要因です。例えば、NIDDK 2021によると、慢性腎臓病（CKD）は、米国の成人の7人に1人以上が罹患しており、合計3,700万人が罹患していると推定されています。

CKDのリスクは、腎臓病の2大原因である糖尿病や高血圧を患っている米国人ではさらに高くなります。腎臓病は糖尿病患者のほぼ3分の1、高血圧患者の5分の1が罹患しています。

さらに、米国疾病予防管理センター（CDC）の「米国における慢性腎臓病」（2021年）によると、CKDの有病率は男性（12％）よりも女性（14％）の方がわずかに高く、ヒスパニック系以外の黒人成人（16％）の方が、ヒスパニック系以外の白人成人（13％）やヒスパニック系以外のアジア人（13％）よりも高いです。したがって、CKDの頻度は市場拡大の原動力となると思われます。

診断プロセスコストの高さが市場成長の妨げになる見込み

腎機能検査のコストが高いこと、新興国や発展途上国での受入率が低いことが市場開拓の足かせとなります。修正処方の結果、腎臓病と臨床診断される人が増えるということは、腎機能を阻害したり、腎臓でうまくろ過されない可能性のある特定の薬剤について、投与量の調整や禁忌の勧告を受ける人が増える可能性があるということです。

COVID-19の影響分析

COVID-19の大流行はヘルスケアシステムと市場に中程度の影響を与えました。2020年4月にmedRXivに発表された研究によると、COVID-19の尿失禁はさまざまな感染症や有害な病気を持つ人にしばしば観察されました。少し軽いタイプのCOVID-19を持つ0歳から12歳の子どもは、尿路COVID-19曝露があることが判明しています。

COVID-19尿路感染症は発症後1日目から5日目の間に確認されました。腎機能マーカーは腎臓の機能を調べるために使われます。いくつかのシグナルは放射性であると同時に非放射性です。これらは腎臓の糸球体濾過率や濃縮・希釈能力（尿細管機能）を示します。腎機能検査はオンラインよりも店頭で購入する人が多いです。

ロシア・ウクライナ戦争の影響分析

ロシア・ウクライナは、普及率が低く、この地域に主要な市場プレーヤーがいないため、世界の腎機能検査市場への影響は最小限と推定されます。しかし、原材料、検査製品、デバイスの輸出入の影響は、予測期間中、世界の腎機能検査市場にほとんど影響を与えないと予測されます。

人工知能の影響分析

人工知能は、世界の子癇前症市場にプラスの影響を与えると予測されます。人工知能を搭載した意思決定支援システムは、ヘルスケア担当者が腎臓の診断と治療の選択肢について十分な情報に基づいた判断を下すのに役立つ。これらのシステムは、患者のデータを分析し、現在の医学的知識と比較し、エビデンスに基づくガイドラインに基づいて提案を行うことができます。これにより、医師は特定の患者に最適な診断検査、薬剤、治療法を選択することができます。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響を与える要因
  • 促進要因
    • 腎機能検査向け製品の発売増加
    • 腎臓病の罹患率の増加
  • 抑制要因
    • 診断プロセスのコストが高くなる
  • 機会
    • 腎機能検査は、ヘルスケア従事者が患者に合わせた個別の治療計画を立てるのに役立ちます
  • 影響分析

第5章 業界分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19の分析

第7章 ロシアとウクライナの戦争分析

第8章 人工知能の影響分析

第9章 製品タイプ別

• ディップスティック
• 試薬
• 使い捨て用品
• その他

第10章 テストの種類別

• 尿検査
• 血液検査
• その他

第11章 エンドユーザー別

• 病院
• 診断センター
• 調査および研究所
• その他

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東とアフリカ

第13章 競合情勢

• 競合シナリオ
• 市場シェア分析
• 合併と買収の分析

第14章 企業プロファイル

• F. Hoffmann-La Roche Ltd
• 会社概要
• 製品ポートフォリオと説明
• 財務概要
• 主な発展
• Nova Biomedical
• Quest Diagnostics
• 77 Elektronika Kft
• ACON Laboratories, Inc.
• Beckman Coulter
• Abbott
• bioMerieux SA
• OPTI Medical
• Siemens Healthineers.

第15章 付録

Market Overview

The Global Kidney Function Tests Market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.4 billion by 2030. The market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.

Kidney function tests identify kidney or renal function disorders and assist doctors in prescribing appropriate medicine. Dilution tests, clearance tests and other types of kidney function tests are available. Kidney diseases such as trouble urinating due to excess bodily fluids, edema in the hands or feet, and swollen face can be identified using a kidney function test.

The factors driving the growth of the market include FDA approvals and the launch of new products by the key players for kidney function tests. For instance, on July 12, 2022, Healthy.io, the global pioneer in integrating the smartphone camera into a medical device, announced that the Minuteful Kidney test has acquired 510(k) clearance from the US Food and Drug Administration (FDA) for home use.

Market Dynamics

Increasing the Prevalence of Kidney Diseases will Drive the Kidney Function Tests Market Growth

The global rise in the incidence and prevalence of chronic kidney disease is a major factor driving the growth of the global kidney function testing market. For instance, according to NIDDK 2021, Chronic kidney disease (CKD) affects more than one in every seven adults in the United States, totaling an estimated 37 million people.

The risk of CKD is even higher for Americans who have diabetes or high blood pressure, the two most frequent causes of kidney disease. Kidney disease affects nearly one-third of people with diabetes and one-fifth of people with high blood pressure.

Additionally, according to the Centers for Disease Control and Prevention's (CDC) Chronic Kidney Disease in the United States, 2021, CKD is slightly more prevalent in women (14%) than in men (12%), and it is more common in non-Hispanic Black adults (16%) than in non-Hispanic white adults (13%) or non-Hispanic Asian people (13%). Thus, the frequency of CKD will fuel market expansion.

High Diagnostic Process Costs are Expected to Hamper the Market Growth

The high cost of kidney function tests, as well as the low acceptance rate in emerging and developing nations, will stifle market expansion. The increased number of people with a clinical diagnosis of kidney disease as a result of the modified formula means that more people may receive recommendations for dose adjustments or contraindications for certain drugs that may interfere with kidney function or be poorly filtered by the kidneys.

COVID-19 Impact Analysis

The pandemic of COVID-19 has had a moderate impact on healthcare systems and the market. According to a study published in medRXiv in April 2020, COVID-19 urine incontinence was often observed in persons with a variety of infectious and harmful illnesses. Children aged 0 to 12 who have a little light type of COVID-19 have been found to have urinary tract COVID-19 exposure.

COVID-19 urinary tract infections were identified between the first and fifth days after the disease's onset. Kidney function markers are used to determine how well the kidneys function. Some signals are radioactive as well as non-radioactive. They demonstrate the kidneys' glomerular filtration rate as well as their concentrating and diluting capacities (tubular function). Many people would rather buy a kidney function test at a store than online.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global kidney function tests market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test products and devices is anticipated to have little influence over the global kidney function tests market in the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is anticipated to impact the global preeclampsia market positively. Artificial intelligence-powered decision support systems can help healthcare personnel make well-informed judgements about renal diagnosis and treatment options. These systems are capable of analyzing patient data, comparing it to current medical knowledge and making suggestions based on evidence-based guidelines. This assists doctors in selecting the best diagnostic tests, drugs or actions for particular patients.

Segment Analysis

The global kidney function tests market is segmented based on product type, test type end user and region.

The Dipstick Segment is Estimated to Hold the Majority of the Kidney Function Tests Market Share During the Forecast Period

The Dipstick product type holds about 47.3% of the total kidney function tests market in the forecast period. Dipstick tests provide rapid results, usually within a few minutes, allowing for immediate assessment of kidney health. They are easy to use and do not require extensive laboratory equipment or specialized training, making them accessible in various healthcare settings, including clinics, emergency rooms and home.

This aids in the diagnosis of a variety of renal and urinary issues, including chronic kidney disease, bladder infections and kidney stones. Furthermore, the increasing number of people and important companies' strategies in renal function testing promote some growth.

For instance, Sweden's Elypta AB raised USD 7.0 million in January 2020 for a urine cancer screening test. Therefore, a patient's urine can reveal a lot of information about their health, increasing the use of dipsticks. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America Holds a Dominant Position in the Global Kidney Function Tests Market

The North American region holds the second-largest share of the global kidney function tests market accounting for approximately 39.4% in the forecast period. Due to well-established healthcare infrastructure, widespread awareness of CKD and favorable reimbursement policies and government initiatives. Furthermore, the region's main manufacturers are focused on inventing innovative products.

For instance, Abbott HealthTab signed a non-assignable, pilot supplier distribution agreement with Abbott in November 2021 for i-STAT Alinity, a handheld blood chemistry analyzer. The partnership allows HealthTab to sell Abbott's POC i-STAT Alinity and associated creatinine tests in Canadian pharmacies, providing patients with important information regarding their kidney functioning.

Competitive Landscape

The major global players in the market include: F. Hoffmann-La Roche Ltd, Nova Biomedical, Quest Diagnostics, 77 Elektronika Kft, ACON Laboratories, Inc., Beckman Coulter, Abbott, bioMerieux SA, OPTI Medical, Siemens Healthineers. among others.

Why Purchase the Report?

• To visualize the global kidney function tests market segmentation based on product type, test type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of kidney function tests market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available in Excel consisting of key products of all the major players.

The Global Kidney Function Tests Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 pages.

Target Audience 2023

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Test Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing product launches for kidney function tests
    • 4.1.1.2. Increasing the prevalence of kidney diseases
  • 4.1.2. Restraints
    • 4.1.2.1. High diagnostic process costs growth
  • 4.1.3. Opportunity
    • 4.1.3.1. Kidney function tests help healthcare providers develop individualized treatment plans for patients
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Impact Analysis

9. By Product Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.1.2. Market Attractiveness Index, By Product Type
• 9.2. Dipsticks
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Reagents
• 9.4. Disposables
• 9.5. Others

10. By Test Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.1.2. Market Attractiveness Index, By Test Type
• 10.2. Urine test
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Blood test
• 10.4. Others

11. By End User

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.1.2. Market Attractiveness Index, By End User
• 11.2. Hospitals
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Diagnostic Centers
• 11.4. Research laboratories and institutes
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Market Share Analysis
• 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

• 14.1. F. Hoffmann-La Roche Ltd
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Nova Biomedical
• 14.3. Quest Diagnostics
• 14.4. 77 Elektronika Kft
• 14.5. ACON Laboratories, Inc.
• 14.6. Beckman Coulter
• 14.7. Abbott
• 14.8. bioMerieux SA
• 14.9. OPTI Medical
• 14.10. Siemens Healthineers.

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us